ANDA Communication Complaints: FDA Takes Licking, Keeps Ticking
Executive Summary
As sponsors vent about uncertain status of their ANDAs, FDA Office of Generic Drugs indicates number of ideas are in process, including providing target action dates for applications without formal review goals.
You may also be interested in...
Goal Date Confusion: The Downside Of Generic Drug Assessment Transparency
ANDA sponsors worry launch plans cannot be finalized if US FDA will not inform them whether their application requires a facility inspection.
Goal Date Confusion: The Downside Of Generic Drug Assessment Transparency
ANDA sponsors worry launch plans cannot be finalized if US FDA will not inform them whether their application requires a facility inspection.
Outlook For Orange Book Update Not Too Rosy
With about 20,000 products eligible for US marketing status report on drugs in Orange Book, there is no timeline for all changes to be made.